CLL Patient Survey

Lymphoma Canada is preparing submissions to the pan­Canadian Oncology Drug Review (pCODR) for: Ibrutinib (Imbruvica) for patients with previously untreated CLL for whom fludarabine-based treatment is considered inappropriate and
Venetoclax (ABT-199) for patients with relapsed/refractory CLL

Thank you to all those who completed a survey! The survey is now closed.

Lymphoma Canada is preparing submissions to the pan­Canadian Oncology Drug Review (pCODR) for:

1. Ibrutinib (Imbruvica) for patients with previously untreated CLL for whom fludarabine-based treatment is considered inappropriate
2. Venetoclax (ABT-199) for patients with relapsed/refractory CLL